Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vanda

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.

Benzinga

3 Biotech Stocks to Watch for Lucrative Gains

The biotech sector’s robust long-term growth is driven by strong government support, the rising foothold of personalized medicine, the growing number of orphan drug formulations, and rapid AI adoption. Hence, biotech stocks G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), and Royalty Pharma (RPRX) could be ideal additions to your watchlist. Keep…

StockNews.com

Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Tesla Stock More Popular Than Ever With Individuals

With retail investors spending tens of billions spent on Tesla shares already purchased this year, the company outpaces any other security by far.

InsideEVs

Why Are Vanda Pharma Shares Plunging Today?

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.

Benzinga

People

Anthony Denier

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Vertex Pharmaceuticals Incorporated

63 stories

EXEL

52 stories

the US Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.